Understanding how genetic changes affect immune responses in squamous cell carcinoma
Dissecting the genetic basis of cancer immune evasion in squamous cell carcinoma
This study is looking at how certain changes in a gene called PIK3CA might help squamous cell carcinoma (a type of cancer) avoid the immune system, and it aims to use this information to make immunotherapy treatments work better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10990206 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that contribute to immune evasion in squamous cell carcinoma (SCC), a type of cancer that can occur in various parts of the body such as the skin and oral cavity. The study focuses on specific mutations in the PIK3CA gene, which may lead to the development of immune-resistant tumor-initiating cells. By examining how these mutations influence the behavior of cancer cells, the research aims to improve the effectiveness of immunotherapy treatments for patients with SCC. Patients may be involved in the research to help identify genetic markers that predict treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with squamous cell carcinoma, particularly those with PIK3CA mutations.
Not a fit: Patients with other types of cancer or those without squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy options for patients with squamous cell carcinoma.
How similar studies have performed: Previous research has shown promising results in understanding genetic factors in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Nicholson, Benjamin — University of Chicago
- Study coordinator: Nicholson, Benjamin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.